Takeda adds reinforcement to its investor charm offensive

Financing and creating enduring confidence around a deal like Takeda’s (TYO: 4502) $62 million purchase of Shire is not straight forward, but the Japanese drugmaker has hired one of the best operators in his field to help with the task.

Atsushi Seki will join the company’s investor relations team next month, bringing with him 10 years of experience as a highly-ranked pharmaceutical research analyst at investment banks.

His most recent role was executive director for investment bank research at Swiss banking giant UBS Group. He has been highly ranked by the Institutional Investor magazine survey for several years, and was recently named the best analyst in the Japan biotechnology and pharmaceuticals sector.